Visirna's VSA001 achieves positive Phase III results in China

Privately-held Chinese firm Visirna Therapeutics has announced that a Phase III trial of VSA001 (plozasiran) has met both its primary and all key secondary endpoints.

The study focused on patients with familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by extremely high triglyceride levels, leading to serious health risks such as acute pancreatitis.

VSA001 is a small interfering RNA (siRNA) therapeutic which has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the US Food and Drug Administration, as well as Orphan Drug designation from the European Medicines Agency.